Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences

NEXT STORY
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
PREV STORY
Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

author_avatar
NASDAQ Market News

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of ...

author_avatar
NASDAQ Market News

Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Board

author_avatar
NASDAQ Market News